Here are some highlights from this past week's earnings coverage from BloggingStocks:

• Bed Bath & Beyond Inc. (NASDAQ: BBBY) Q1 earnings tumbled while revenues rose.
• Casella Waste Systems Inc. (NASDAQ: CWST) posted a narrower-than-expected Q4 loss.
• CKE Restaurants Inc. (NYSE: CKR) Q1 earnings increased but its revenue slipped.
• Darden Restaurants Inc. (NYSE: DRI) swung to a Q4 profit on strong sales at Olive Garden.
• Ericsson (NASDAQ: ERIC) said it might not see Q2 profit growth on lower demand and shipping delays.
• General Mills Inc. (NYSE: GIS) Q4 earnings declined but were in line with expectations.
• Gerber Scientific Inc. (NYSE: GRB) reported solid Q4 and full-year results that pleased investors.
• IHS Inc. (NYSE: IHS) beat Q2 expectations and posted record quarterly cash flow from operations.
• Jabil Circuit Inc. (NYSE: JBL) stronger-than-expected Q3 results led to an analyst's upgrade.
• KB Home (NYSE: KBH) widened its Q2 loss due to weak sales and falling prices.
• Kroger Co. (NYSE: KR) beat Q1 expectations as consumers sought discounts on food and gas.
• Monsanto Co. (NYSE: MON) beat Q3 earnings estimates but fell short of revenue estimates.
• Nike Inc. (NYSE: NKE) posted better-than-expected Q4 results boosted by international strength.
• Oracle Corp. (NASDAQ: ORCL) posted strong Q4 results that topped analysts' expectations (see transcript).

Symmetry Medical (NYSE: SMA) makes implants and related instruments for orthopedic device manufacturers, primarily in the United States and the United Kingdom. Its devices are used in reconstructive surgeries to replace or repair hips, knees, shoulders, ankles and elbows. The company also designs, develops and produces products for companies in other segments of the medical device market, including arthroscopy, dentistry, laparoscopy and endoscopy. As a sideline, the firm manufactures aerofoils and aircraft engine parts for a few aerospace customers.

Symmetry pleased the Street earlier in the week, when it announced Q1 EPS of 20 cents and revenues of $101.9 million. Analysts had been expecting 14 cents and $88.4 million. The CEO attributed success to increased demand across the orthopedic market and the effects of recent acquisitions. Management also guided FY08 EPS to 75-77 cents (72 cent consensus) and FY08 revenues to $395-$405 million ($359.21M consensus).